Democratizing GLP-1 drugs via price caps
The guest announced a policy to cap cash prices for GLP-1 drugs at ~$200, arguing it will save taxpayer money long-term by reducing obesity-driven chronic diseases and democratizing access beyond the wealthy.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.